Influencing Physician Prescribing: Does Clinical Data Work?
At the 2002 American Heart Association meeting last November, many cardiologists could be heard expressing frustration over how to interpret and apply clinical data in their day-to-day practices. At the same time, thought leaders involved in generating the periodic guideline recommendations designed to interpret such data could be heard complaining about the low rate of compliance with guidelines. Both are addressing the same core issue: How does data change practice patterns for the better, and how can that change be made rapidly and effectively given the time it takes to complete and analyze a data set on potential outcomes?
by Mark L. Ratner
At the 2002 American Heart Association (AHA) meeting held in
Chicago last November, many cardiologists attending presentations
of long-term follow-up data from clinical trials could be heard
expressing frustration over how to interpret and apply those data
in their day-to-day practices. Their consternation was evident both
in questions in the scientific sessions and in hallway discussions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.
Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.
Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.
